Positive News SentimentPositive NewsNASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis $1.14 +0.02 (+2.05%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enlivex Therapeutics Stock (NASDAQ:ENLV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enlivex Therapeutics alerts:Sign Up Key Stats Today's Range$1.11▼$1.1550-Day Range$0.89▼$1.2652-Week Range$0.81▼$1.76Volume18,081 shsAverage Volume128,683 shsMarket Capitalization$27.03 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewEnlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Read More… Enlivex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreENLV MarketRank™: Enlivex Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 358th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingEnlivex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Enlivex Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Enlivex Therapeutics are expected to grow in the coming year, from ($0.70) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enlivex Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.36% of the float of Enlivex Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 23.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.36% of the float of Enlivex Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enlivex Therapeutics has recently decreased by 23.63%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentEnlivex Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enlivex Therapeutics this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.02% of the stock of Enlivex Therapeutics is held by institutions.Read more about Enlivex Therapeutics' insider trading history. Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENLV Stock News HeadlinesEnlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVJune 13, 2025 | usatoday.comEnlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in BarcelonaJune 11, 2025 | nasdaq.com"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.July 1 at 2:00 AM | Crypto 101 Media (Ad)Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of RheumatologyJune 10, 2025 | globenewswire.comEnlivex Selected to Present at Israeli BioMed 2025 ConferenceMay 20, 2025 | globenewswire.comEnlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World CongressApril 23, 2025 | globenewswire.comEnlivex enrols all patients in Phase II stage of knee osteoarthritis trialApril 23, 2025 | msn.comEnlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee OsteoarthritisApril 23, 2025 | nasdaq.comSee More Headlines ENLV Stock Analysis - Frequently Asked Questions How have ENLV shares performed this year? Enlivex Therapeutics' stock was trading at $1.17 at the beginning of 2025. Since then, ENLV shares have decreased by 4.3% and is now trading at $1.12. View the best growth stocks for 2025 here. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) issued its quarterly earnings data on Friday, May, 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META). Company Calendar Last Earnings5/30/2025Today7/01/2025Next Earnings (Estimated)8/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENLV CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+792.9%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.67% Return on Assets-50.52% Debt Debt-to-Equity RatioN/A Current Ratio7.20 Quick Ratio7.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book1.12Miscellaneous Outstanding Shares23,650,000Free Float20,747,000Market Cap$26.49 million OptionableOptionable Beta0.74 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:ENLV) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
